Rheumatoid Arthritis
Conditions
Interventions
None listed
Sponsors
Department of Immunology and Rheumatology, Unit of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with rheumatoid arthritis who attend or are in hospital at Department of immunology and Rheumatology or Department of Orthopaedic Surgery, Nagasaki University Hospital Inclusion criteria Patients who meet either of the following [2] and [3] as well as all of [1], [4], and [5] are included. [1] Patients with rheumatoid arthritis who are diagnosed based on the American College of Rheumatology (ACR) classification criteria for rheumatoid arthritis (revised in 1987) or the 2010 ACR-European League Against Rheumatism (EULAR) classification criteria for rheumatoid arthritis [2] Patients who are scheduled to newly start administration of abatacept against RA [3] Patients who receive a new antirheumatic drug other than abatacept and molecular target drugs (TNF inhibitor, IL-6 inhibitor, tofacitinib) against RA (control group) [4] Any sex [5] Patients at the age of 20 or more from whom consent is obtained in written form by the patient's own will after they are sufficiently explained for participating in the study and understand well
Exclusion criteria
Exclusion criteria: [1] A patient who is pregnant or may be pregnant [2] A patient who has following disease that may change the bone structure: A patients who has paralysis due to cerebral stroke, a patient who receives hemodialysis, a patient undergoing treatment for malignant tumor, a patient who takes a drug for osteoporosis or steroid orally [3] A patient who has been administered with a molecular target drug (TNF inhibitor, IL-6 inhibitor, tofacitinib) including abatacept [4] A patient who cannot keep his/her extremities still [5] A patient who is determined as inappropriate as a subject for other reasons by a principle investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Volume changes after 12 months of bone erosion that is detected by High Resolution peripheral Quantitative CT (HR-pQCT) in the evaluation joint during CTLA4-Ig treamtne. | — |
Secondary
| Measure | Time frame |
|---|---|
| -Changes of bone microstructure compared with baseline -Correlation of Bone microstructure changes and joint ultrasound findings,biomarker -Correlation of bone microstructure changes and bone mineral density -Correlation of bone microstructure changes and joint MRI,joint XP. | — |
Countries
Japan
Contacts
Public ContactNaoki Iwamoto
Graduate School of Biomedical Sciences, Nagasaki University Department of Immunology and Rheumatology, Advanced Preventive Medical Sciences.
Outcome results
None listed